Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Boosted by National Bank of Canada FI

National Bank of Canada FI grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 266,361.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,385,600 shares of the company's stock after acquiring an additional 1,385,080 shares during the quarter. National Bank of Canada FI owned about 1.11% of Apellis Pharmaceuticals worth $44,214,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company's stock valued at $112,036,000 after purchasing an additional 735,160 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Apellis Pharmaceuticals by 52.9% during the third quarter. BNP Paribas Financial Markets now owns 159,700 shares of the company's stock worth $4,606,000 after acquiring an additional 55,282 shares during the last quarter. Old West Investment Management LLC purchased a new stake in Apellis Pharmaceuticals during the 3rd quarter valued at about $2,953,000. Teacher Retirement System of Texas raised its holdings in Apellis Pharmaceuticals by 9.4% in the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock valued at $691,000 after acquiring an additional 1,864 shares during the last quarter. Finally, KBC Group NV lifted its stake in Apellis Pharmaceuticals by 3,862.3% in the 4th quarter. KBC Group NV now owns 104,287 shares of the company's stock worth $3,328,000 after purchasing an additional 101,655 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Apellis Pharmaceuticals Stock Performance

Shares of APLS traded down $0.77 during mid-day trading on Monday, reaching $19.20. 1,042,510 shares of the company's stock were exchanged, compared to its average volume of 2,093,521. Apellis Pharmaceuticals, Inc. has a 52-week low of $18.25 and a 52-week high of $57.85. The business's fifty day simple moving average is $26.22 and its 200-day simple moving average is $28.96. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock has a market capitalization of $2.41 billion, a PE ratio of -9.43 and a beta of 0.85.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08. The company had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals's revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.73) earnings per share. On average, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

APLS has been the subject of several recent research reports. Scotiabank increased their price target on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a "sector perform" rating in a report on Wednesday, April 2nd. The Goldman Sachs Group dropped their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Royal Bank of Canada reduced their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a "sector perform" rating on the stock in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Finally, Wedbush reduced their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $45.59.

Insider Activity

In other news, CAO James George Chopas sold 1,096 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total value of $33,351.28. Following the completion of the sale, the chief accounting officer now owns 48,138 shares of the company's stock, valued at $1,464,839.34. This represents a 2.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel David O. Watson sold 5,569 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,238 shares of company stock valued at $1,857,510 over the last quarter. Company insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).